Month: February 2025

Gastric cancer is the fifth most common malignancy globally. For advanced gastric cancer, systemic treatments such as chemotherapy and targeted therapies are the primary treatment options. However, HER2-negative advanced gastric cancer patients have long lacked effective targeted drugs. Claudin 18.2 (CLDN18.2) is a tight junction protein, and nearly 40% of patients with HER2-negative gastric cancer exhibit high expression of CLDN18.2. Zolbetuximab, a monoclonal antibody targeting CLDN18.2, can mediate antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) effects in CLDN18.2-positive gastric cancer cells.

The Breast Cancer Committee of the Chinese Society of Clinical Oncology (CSCO BC) has developed the CSCO Breast Cancer Diagnosis and Treatment Guidelines (hereafter referred to as the CSCO BC Guidelines), which have become a crucial reference for Chinese clinicians, serving as a "navigation tool" for clinical decision-making. With the rapid progress of clinical oncology, especially the continuous emergence of original Chinese research and treatment strategies, the CSCO BC Guidelines have not only stayed at the forefront of international developments but have also incorporated more "Chinese characteristics." This has attracted increasing attention from international experts. Recently, the English version of the CSCO BC Guidelines was published in the Translational Breast Cancer Research (TBCR), further showcasing China's experience and wisdom in breast cancer management to the global oncology community. Oncology Frontier invited Dr. Zefei Jiang, Dr. Chunfang Hao, Dr. Xu Liang, Dr. Jin Yang, Dr. Min Yan, and Dr. Yueping Liu to provide an overview of the key updates to the CSCO BC Guidelines and share their insights with international peers through this global platform.

Kidney cancer and urothelial carcinoma are among the most common malignancies of the urinary system and are known for their strong immunogenicity. This characteristic theoretically makes them ideal candidates for immune checkpoint inhibitors. However, results from multiple phase III randomized controlled trials (RCTs) have failed to demonstrate a significant overall survival (OS) benefit for immunotherapy in these cancers. The question remains: how should clinicians approach immunoadjuvant therapy in clinical practice? During the recent ASCO GU Annual Meeting, leading urologic oncology experts from MD Anderson Cancer Center shared their insights.

A groundbreaking genomic study on clinically advanced urothelial bladder cancer (CAUBC) in young-onset bladder cancer (YOUC) patients is reshaping our understanding of age-related tumor biology. Analyzing 9,411 cases, researchers discovered distinct genetic and mutational differences between younger (<50) and older (>50) patients, revealing key insights that could transform treatment strategies.

Colorectal cancer (CRC) remains a significant global health burden, with recurrence being a major concern even after standard treatment. The ALASCCA trial, a biomarker-driven randomized study, explored the role of…

Androgen deprivation therapy (ADT) remains the cornerstone treatment for patients with metastatic prostate cancer. However, it is frequently associated with adverse effects such as vasomotor symptoms, including hot flashes, fatigue, and bone density loss, which significantly impact patients' quality of life. The rapid advancements in therapeutic strategies for advanced prostate cancer have led to investigations into alternative approaches. A study presented at the 2025 ASCO GU Annual Meeting introduced transdermal estrogen as a potential ADT alternative, offering a new option for metastatic prostate cancer patients.